Key result
Anthracycline-based chemotherapy remains the foundational treatment for PMBCL despite ongoing controversies.
This review discusses controversial topics in the management of primary mediastinal large B-cell lymphoma, including chemotherapy regimens, radiotherapy, and PET scan assessment.
Anthracycline regimens remain PMBCL backbone; leaves open optimal third-generation regimens, radiotherapy, and PET assessment.
Primary mediastinal large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma, which has distinct clinical and molecular features, many of which are similar to that of nodular sclerosing/classical Hodgkin lymphoma. Anthracycline-based chemotherapy forms the foundation for treatment of this lymphoma. This review will discuss controversial topics that warrant further study, such as the superiority of third generation regimens over CHOP-based regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone), the use of involved field radiotherapy, and the assessment of clinical response by positron emission tomography scans.
No takes yet. Share an insight, caveat, or question.
Faris et al. (2017) conducted a review in Primary mediastinal large B-cell lymphoma. Anthracycline-based chemotherapy was evaluated. Anthracycline-based chemotherapy forms the foundation for treating primary mediastinal large B-cell lymphoma, though controversies remain regarding third-generation regimens, radiotherapy, and PET.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: